Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Accumulated Expenses: 2015-2025

Historic Other Accumulated Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $1.5 million.

  • Seres Therapeutics' Other Accumulated Expenses fell 77.38% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 77.38%. This contributed to the annual value of $2.2 million for FY2024, which is 21.97% down from last year.
  • Seres Therapeutics' Other Accumulated Expenses amounted to $1.5 million in Q3 2025, which was up 45.06% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Other Accumulated Expenses peaked at $8.0 million during Q2 2023, and registered a low of $1.0 million during Q2 2025.
  • Its 3-year average for Other Accumulated Expenses is $3.7 million, with a median of $2.8 million in 2023.
  • Per our database at Business Quant, Seres Therapeutics' Other Accumulated Expenses surged by 348.03% in 2023 and then crashed by 77.38% in 2025.
  • Seres Therapeutics' Other Accumulated Expenses (Quarterly) stood at $3.6 million in 2021, then increased by 0.30% to $3.6 million in 2022, then decreased by 23.93% to $2.8 million in 2023, then declined by 21.97% to $2.2 million in 2024, then crashed by 77.38% to $1.5 million in 2025.
  • Its Other Accumulated Expenses was $1.5 million in Q3 2025, compared to $1.0 million in Q2 2025 and $2.6 million in Q1 2025.